New MEK inhibitor, trametinib, improves survival in advanced melanoma

Increased risk of breast cancer among young women treated with radiation as a child

First effective treatment for chemotherapy-induced peripheral neuropathy

Afatinib delays progression of advanced lung adenocarcinomas

Costly drugs versus paclitaxel as first line therapy for locally advanced or metastatic breast cancer

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-positive breast cancer

Increased progression-free survival in advanced lung cancer with afatinib

Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer

Changing the standard treatment for lymphoma with bendamustine

Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer

Continuing bevacizumab with second-line chemotherapy for colorectal cancer